JP2024539093A5 - - Google Patents

Info

Publication number
JP2024539093A5
JP2024539093A5 JP2024523413A JP2024523413A JP2024539093A5 JP 2024539093 A5 JP2024539093 A5 JP 2024539093A5 JP 2024523413 A JP2024523413 A JP 2024523413A JP 2024523413 A JP2024523413 A JP 2024523413A JP 2024539093 A5 JP2024539093 A5 JP 2024539093A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
nucleoside
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047102 external-priority patent/WO2023069495A1/en
Publication of JP2024539093A publication Critical patent/JP2024539093A/ja
Publication of JP2024539093A5 publication Critical patent/JP2024539093A5/ja
Pending legal-status Critical Current

Links

JP2024523413A 2021-10-19 2022-10-19 ２’－デオキシ－２’－ｆ－２’－ｃ－メチルヌクレオチドを有するオリゴヌクレオチド Pending JP2024539093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257289P 2021-10-19 2021-10-19
US63/257,289 2021-10-19
PCT/US2022/047102 WO2023069495A1 (en) 2021-10-19 2022-10-19 Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides

Publications (2)

Publication Number Publication Date
JP2024539093A JP2024539093A (ja) 2024-10-28
JP2024539093A5 true JP2024539093A5 (https=) 2025-10-23

Family

ID=86059614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523413A Pending JP2024539093A (ja) 2021-10-19 2022-10-19 ２’－デオキシ－２’－ｆ－２’－ｃ－メチルヌクレオチドを有するオリゴヌクレオチド

Country Status (4)

Country Link
US (1) US20250223588A1 (https=)
EP (1) EP4419536A4 (https=)
JP (1) JP2024539093A (https=)
WO (1) WO2023069495A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024259190A2 (en) * 2023-06-15 2024-12-19 Alnylam Pharmaceuticals, Inc. 5'-modified monomers, oligonucleotides and double-stranded rnas
CN118063533B (zh) * 2023-09-18 2024-08-27 广州必贝特医药股份有限公司 修饰的核苷酸化合物、其寡聚核苷酸及其应用
WO2025260011A1 (en) * 2024-06-14 2025-12-18 Alnylam Pharmaceuticals, Inc. 5'-modified monomers, oligonucleotides and double-stranded rnas
WO2025259992A1 (en) * 2024-06-14 2025-12-18 Alnylam Pharmaceuticals, Inc. 5'-modified monomers, oligonucleotides and double-stranded rnas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100447A2 (en) * 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US20110130440A1 (en) * 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
US20120059045A1 (en) * 2008-10-24 2012-03-08 Isis Pharmaceuticals, Inc. Methods of using oligomeric compounds comprising 2'-substituted nucleosides
AU2010221419B2 (en) * 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
WO2011005860A2 (en) * 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
HUE051986T2 (hu) * 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
WO2020051398A1 (en) * 2018-09-06 2020-03-12 Aptamir Therapeutics, Inc. Metabolic benefits of short mir-22 mirna antagomir therapies
US11820985B2 (en) * 2019-03-26 2023-11-21 University Of Massachusetts Modified oligonucleotides with increased stability
AU2020358016A1 (en) * 2019-10-02 2022-04-21 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering RNA with minimal fluorine content

Similar Documents

Publication Publication Date Title
JP2024539093A5 (https=)
JP2022535911A5 (https=)
JP2021521140A5 (https=)
JP2022528487A5 (https=)
JP2022546557A5 (https=)
JP2022551269A5 (https=)
JP2021507709A5 (https=)
JP2020503070A (ja) α−１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。
JP2012509258A5 (https=)
JP2023541415A (ja) 治療薬の送達用脂質複合体
JP2006516151A (ja) 改良された薬力学的特性を有する多価アプタマー治療剤ならびにそれらの作製方法および使用法
FI115215B (fi) Menetelmä oligonukleotidianalogien valmistamiseksi, joista on muodostettu 3'-johdannaisia ja joissa on ei-nukleotidisiä ryhmiä ja niiden käyttö
JP2025522429A (ja) 中枢神経系組織への治療薬の送達のための脂質結合体
JP2025500547A5 (https=)
JP2024525713A5 (https=)
Watts The medicinal chemistry of antisense oligonucleotides
CA2834200A1 (en) A method for manufacturing pegylated oligonucleotides
AU2021340710A1 (en) Skeletal muscle delivery platforms and methods of use
JP2023528016A5 (https=)
JP2023505489A (ja) ポリホスファゼン薬物担体
WO2018177881A1 (en) Unylinker rapid cleavage
CN113507942A (zh) 分子的细胞内靶向
JP2024521907A5 (https=)
Sekine et al. Chemical synthesis of oligonucleotides by use of phenylthio group
EP3630787B1 (en) Tetramolecular parallel g-quadruplex-forming hydrophobically modified oligonucleotides